November 12, 2014
Notes: Nikkola, Jussi
J Gastrointest Surg. 2014 Jan;18(1):164-70; discussion 170-1. doi: 10.1007/s11605-013-2279-1. Epub 2013 Sep 4.
Author Address: School of Medicine, University of Tampere, Tampere, Finland.
Reference Type: Journal Article
Record Number: 4866Author: Niyaz, B., Zhao, K. L., Liu, L. M., Chen, C., Deng, W. H., Zuo, T., Shi, Q. and Wang, W. X.
Title: Rosiglitazone attenuates the severity of hyperlipidemic severe acute pancreatitis in rats
Journal: Exp Ther Med
Short Title: Rosiglitazone attenuates the severity of hyperlipidemic severe acute pancreatitis in rats
Alternate Journal: Experimental and therapeutic medicine
ISSN: 1792-0981 (Print)
Accession Number: 24137303
Abstract: Peroxisome proliferator-activated receptor-gamma (PPAR-gamma) ligand regulates adipocyte differentiation and insulin sensitivity, and exerts antihyperlipidemic and anti-inflammatory effects. However, the mechanisms by which PPAR-gamma ligands affect hyperlipidemia with severe acute pancreatitis (SAP) have not been fully elucidated. The present study investigated the effects of rosiglitazone, a PPAR-gamma ligand, on hyperlipidemia with SAP in a rat model. The hyperlipidemia was induced with a high-fat diet and SAP was induced by the administration of sodium taurocholate (TCA). The hyperlipidemia was shown to aggravate the severity of the sodium taurocholate-induced SAP. However, rosiglitazone demonstrated significant antihyperlipidemic and anti-inflammatory effects in the rats with high-lipid diet-induced hyperlipidemia and SAP.
Notes: Niyaz, Batur